Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care
Headache
P1 - Poster Session 1 (8:00 AM-9:00 AM)
12-005
Migraine with its high prevalence rate (~14%) imposes high burden and cost on patients and the healthcare system. Given the limited availability of such data we conducted an in-depth analysis of a substantial US payer dataset.
To compare the populations of individuals with chronic migraine and with other migraine headache types to a matched reference (comparator) population with regards to migraine-specific costs of care.
We analyzed recent (8/1/2018 - 7/31/2021) medical and pharmacy data from Health Verity for N=187,780. Baseline and Follow-up are defined as 12 months prior to and after the Index, respectively. Migraine cases were matched to a control group on demographic, geographic, comorbidity, and time-based variables. N = 76,684 migraine cases matched to 76,684 non-migraine controls.
At Baseline migraine group  had significantly higher costs of care in every category measured: inpatient ($160.02 PPPY (per-patient-per-year); 28.7% higher) , emergency department ($261.16 PPPY; 244.4% higher), PCP visits ($400.75 PPPY; 125.3% higher), neurology visits ($92.66 PPPY; 954.6% higher)., other outpatient visits ($1,507.50 PPPY; 125.9% higher),  other medical services ($212.20 PPPY; 105.3% higher), and pharmacy. Compared to controls, all-cause medical care and all-cause pharmacy costs were 110.1% and 71.9% higher among migraine cases. Total healthcare costs were $3,401.19 higher among cases than controls, a difference of 98.3% higher costs. Similar results were noted for differences in costs in the Follow-Up period.
This retrospective cohort analysis underscores the significant economic burden imposed by migraine during both baseline and follow-up periods across all tested categories. Our findings suggest the persistent impact of migraine on healthcare costs, emphasizing the pressing need for effective strategies to manage treatment solutions more efficiently for individuals grappling with migraine.
Authors/Disclosures
Alankar Gupta, MD (Click Therapeutics)
PRESENTER
Dr. Gupta has received personal compensation for serving as an employee of Click Therapeutics.
No disclosure on file
No disclosure on file
No disclosure on file
Shaheen E. Lakhan, MD, PhD, MEd, FAAN Dr. Lakhan has received personal compensation for serving as an employee of Zogenix, Fern Health, Thriveworks, The Learning Corp, Click Therapeutics. Dr. Lakhan has received personal compensation in the range of $1,000,000+ for serving as a Consultant for Shaheen Lakhan, MD, PhD, LLC. Dr. Lakhan has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine, Fern Health, Lin Health. Dr. Lakhan has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Click Therapeutics, SpineThera. Dr. Lakhan has stock in Zogenix, NeuroSport, Click Therapeutics, SpineThera.